SCHEMBL124904

SCHEMBL124904

COC1=CC(=O)CC(C)(C)C1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KMT2A Q03164 4/20 0.51
MAPT P10636 3/20 0.51
HPGD P15428 3/20 0.51
RECQL P46063 1/20 0.47
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1128004 0.78 ALDH1A1 (0.47) ALDH1A1KMT2AMAPTHPGDRECQL
SCHEMBL6164008 0.76 HPGD (0.62) ALDH1A1KMT2AMAPTHPGDGAA
SCHEMBL10795663 0.75 TSHR (0.54) ALDH1A1KMT2AMAPTHPGDRECQL
SCHEMBL25440184 0.74 KMT2A (0.74) ALDH1A1KMT2AMAPTHPGDNCOA1
SCHEMBL23773682 0.74 ALDH1A1 (0.44) ALDH1A1KMT2AMAPTHPGDRECQL
SCHEMBL10795656 0.72 ALDH1A1 (0.57) ALDH1A1KMT2AMAPTHPGDGAA
SCHEMBL9196237 0.72 HPGD (0.57) ALDH1A1KMT2AMAPTHPGDGAA
SCHEMBL9298611 0.71 KMT2A (0.56) ALDH1A1KMT2AMAPTHPGDGAA
SCHEMBL11179702 0.71 KMT2A (0.46) ALDH1A1KMT2AMAPTHPGDNCOA1
SCHEMBL25440265 0.71 KMT2A (0.65) ALDH1A1KMT2AMAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074861-A1 Anticonvulsant Compounds OWEN BARRY PHARMACEUTICALS INC (CA) 2025-03-06 US disclosed
US-20250011333-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2025-01-09 US disclosed
US-11952338-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS INC. (CA) 2024-04-09 US disclosed
US-11345652-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS (CA) 2022-05-31 US disclosed
US-11345652-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS (CA) 2022-05-31 US disclosed
US-20210300935-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS Nerviano Medical Sciences, S.R.L. (IT) 2021-09-30 US disclosed
US-20210300935-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS Nerviano Medical Sciences, S.R.L. (IT) 2021-09-30 US disclosed
US-20210017116-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2021-01-21 US disclosed
US-20210017116-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2021-01-21 US disclosed
US-20200148623-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2020-05-14 US disclosed
US-7482354-B2 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-27 US disclosed
US-7482354-B2 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-27 US disclosed
US-7482354-B2 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-27 US disclosed
EP-1853578-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2007-11-14 EP disclosed
US-20070185143-A1 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-08-09 US disclosed
US-20070185143-A1 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-08-09 US disclosed
US-20070185143-A1 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-08-09 US disclosed
WO-2006088716-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2006-08-24 WO disclosed
EP-1636236-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2006-03-22 EP disclosed
WO-2004104007-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300935-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP4K2 ALDH1A1 3081/4885KMT2A 1627/4885MAPT 2476/4885
US-11952338-B2 Anticonvulsant compounds GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885KMT2A 2288/4885MAPT 1725/4885
US-20210017116-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885KMT2A 2288/4885MAPT 1725/4885
US-20250011333-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP4K2 ALDH1A1 3081/4885KMT2A 1627/4885MAPT 2476/4885
US-20070185143-A1 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors MAP3K5, MAP3K9, MAP3K19 ALDH1A1 3008/4885KMT2A 1394/4885MAPT 1972/4885
US-20200148623-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885KMT2A 2288/4885MAPT 1725/4885
US-11345652-B2 Anticonvulsant compounds GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885KMT2A 2288/4885MAPT 1725/4885
US-20250074861-A1 Anticonvulsant Compounds GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885KMT2A 2288/4885MAPT 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.